scholarly journals Role of periostin in evaluating the responsiveness of allergic patients to allergen-specific immunotherapy

2022 ◽  
Vol 21 (1) ◽  
pp. 184-190
Author(s):  
Nashwa M Selim ◽  
Somia El Sheikh ◽  
Wafaa S Metwally
Keyword(s):  
Specific Immunotherapy ◽  
Medical Science ◽  
Serum Levels ◽  
Total Serum ◽  
Serum Samples ◽  
Allergen Specific Immunotherapy ◽  
Prick Test ◽  
Symptom Scores ◽  
Before And After ◽  
One Year

Objectives: Allergen-specific immunotherapy (AIT) has been considered the most effective treatment for IgE mediated allergies, especially respiratory allergies. Several biomarkers have been developed to evaluate the clinical efficacy of AIT, yet none of them have been thoroughly validated. So our objective here is to investigate the usefulness of periostin as a biomaker for monitoring the efficacy of allergen immunotherapy. Materials and methods: This study included 46 healthy non-atopic volunteers and 46 patients with allergic rhinitis (AR). They were sensitized only to date palm pollen. The participants were tested by skin prick test and total serum IgE levels were measured. Serum samples were collected from healthy subjects and allergic patients before and after the one-year AIT. Serum levels of periostin, eotaxin, and sIL-2R were estimated by ELISA. Symptom scores in the allergic patients were also evaluated before and after completing one year AIT. Results: There is a significant increase in serum levels of IgE, periostin, sIL-2R, and eotaxin in allergic patients as compared to healthy controls. Symptom scores, sIL-2R and serum periostin levels were significantly decreased after one-year AIT in AR patients. Conclusion: Periostin can be used as a biomarker to evaluate AIT efficacy in AR patients. Bangladesh Journal of Medical Science Vol. 21(1) 2022 Page : 184-190

scholarly journals Dynamics of class E and G immunoglobulins under the influence of combined allergen-specific immunotherapy in patients with allergic rhinitis with combined sensitization to pollen and household allergens

2020 ◽  
pp. 42-48
Author(s):  
E.М Dityatkovska ◽  
S.V. Biletska
Keyword(s):  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Immunoglobulin E ◽  
Skin Tests ◽  
Total Serum ◽  
Combination Immunotherapy ◽  
Pollen Allergens ◽  
Allergen Specific Immunotherapy ◽  
Prick Test ◽  
Specific Combination

The aim of this study is to assess the dynamics of immunoglobulin E and G under the influence of combined allergen-specific immunotherapy (ASIT) in patients with allergic rhinitis with combined sensitization to pollen and household allergens. Materials and methods: The study involved 49 patients, residents of Dnipro city, of working age (35,5±1,5 years), of whom 24 (49,0%) - women and 25 (51,0%) - men. All patients were diagnosed with allergic rhinitis with average disease duration of 9,2 ±1,1 year, who underwent allergy examination - skin tests - prick test with pollen and household allergens and/or methods of allergy component diagnosis ALEX. The number of pollen allergens in one patient was 4,6±0,4 on average. All patients received one course of pre-season ASIT allergen according to the express scheme. Patients in the main group (31 patients) received a combined ASIT with solutions of pollen and household allergens. 18 patients in the comparison group received ASIT only with pollen allergens. Clinical groups were homogeneous in age, sex, duration of the disease, as well as the average number of pollen allergens. Results: The obtained results and their analysis show that the use of allergen-specific combination immunotherapy in patients with allergic rhinitis with combined sensitization to pollen allergens causes a more significant effect on the activation of the immune response, which was revealed by reduced relative to baseline lgE production by 41,9% (p<0,001) and an increase in lgG by 7,5% (p<0,05). The production of total serum in patients with allergic rhinitis before treatment and under the influence of ASIT was the opposite to the dynamics of lgG production. The positive results of immunological studies convincingly prove the benefits and effectiveness of allergen-specific combination immunotherapy in the treatment of patients with allergic rhinitis with combined sensitization to pollen and household allergens.

scholarly journals A Randomized, Triple-blind Placebo-controlled Trial to Determine the Effect of Saffron on the Serum Levels of MMP-9 and TIMP-1 in Patients with Multiple Sclerosis

2020 ◽  
Author(s):  
Fatemeh Ghasemi Sakha ◽  
Amirreza Azimi Saeen ◽  
Seyed Mohammad Moazzeni ◽  
Farnaz Etesam ◽  
Gholamhassan Vaezi
Keyword(s):  
Multiple Sclerosis ◽  
Serum Level ◽  
Controlled Trial ◽  
Study Finding ◽  
Serum Levels ◽  
Cell Trafficking ◽  
Serum Samples ◽  
Before And After ◽  
One Year ◽  
Group B

Matrix metalloproteinases-(MMP)-9 facilitates the migration of T-cells to central nervous system (CNS), while (Tissue inhibitor of metalloproteinases-1) TIMP-1 inhibits the function of MMP-9. This study aimed to determine the appropriate treatment option for multiple sclerosis (MS). Forty-three relapsing-remitting MS (RRMS) patients were randomly divided into two groups of 22 (group A, placebo) and 21 (group B, Saffron pill) individuals. Serum samples were collected from patients’ blood before using the Saffron pills/placebo pills and then after 12 months. The serum level of MMP-9 and its inhibitor, as well as TIMP-1, were measured by ELISA kits. Data were analysed using SPSS version 13. MMP-9 serum levels noticeably decreased in patients with MS following 12 months of treatment with Saffron pills (p=0.006) while the changes were not significant before and after 12 months of treatment with placebo pills. Although the levels of TIMP-1 increased significantly after one year treating with Saffron pills (p=0.0002), a considerable difference was not observed before and after taking the placebo pills. The study finding revealed that 12-months treatment with Saffron could have a significant role in reducing the serum level of MMP-9 and increasing the serum level of TIMP-1 in RRMS patients. Therefore, modulating the serum levels of MMP-9 as an important regulator of T cell trafficking to the CNS might be a promising strategy in the treatment of MS patients.

scholarly journals AB0042 CYTOKINE NETWORK ELUCIDATED BY THE QUANTIFICATION OF MULTIPLE CYTOKINES IN THE SERUM SEQUENTIALLY SAMPLED FROM RA PATIENTS WHO WERE TREATED WITH BIOLOGIC DMARDS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1323.2-1324
Author(s):  
K. Sato ◽  
S. Mamada ◽  
C. Hayashi ◽  
T. Nagashima ◽  
S. Minota
Keyword(s):  
Bone Erosion ◽  
Feedback System ◽  
Serum Levels ◽  
Type I Interferons ◽  
Type I ◽  
Serum Samples ◽  
Cytokine Network ◽  
Biologic Dmards ◽  
Type I Ifns ◽  
Before And After

Background:Biologic disease modifying anti-rheumatic drugs (DMARDs) have demonstrated that proinflammatory cytokines such as interleukin (IL-) 6 and tumor necrosis factor (TNF) play important roles in the pathogenesis of rheumatoid arthritis (RA). Other cytokines, such as type I interferons (IFNs), are also implicated in its pathogenesis (ref 1). However, the complete picture of the cytokine network involved in RA remains to be elucidated.Objectives:By quantifying sets of cytokines in the serum of RA patients before and after treatment with various biologic DMARDs, we sought to determine the effects of drugs on (A) type I IFNs, (B) soluble IL-6 receptors, and (C) other cytokines.Methods:52 patients with RA were treated with various biologic DMARDs (tocilizumab (TOC): 16, abatacept (ABT): 15, and TNF inhibitors (TNFi): 21). Serum samples were obtained (1) before, (2) approximately 4 weeks after (3) and approximately 12 weeks after the initiation of treatment. A suspension bead-array system was used for analysis; Bio-Plex Human Cytokine 17-plex Assay kits and Express Custom Panels (Bio-Rad), including IFN-β, IFN-α2, soluble IL-6 receptor α (sIL6Rα) and gp130 were used.Results:(1) As expected, the disease activity score 28-joiny count (DAS28) using the erythrocyte sedimentation rate (ESR) significantly decreased in all three groups (TOC, ABT and TNFi) by 12 weeks.(2) IFN-α2 was barely detected in the serum samples. IFN-β seemed to increase slightly in the ABT group, but the increase was not statistically significant.(3) The levels of sIL6Rα did not change substantially. Those of gp130 decreased slightly but significantly in the TOC group by 12 weeks.(4) The levels of IL-6 decreased significantly in the ABT group by 12 weeks. Those in the TNFi group decreased significantly at 4 weeks but not 12 weeks (Fig. 1A).(5) The levels of IL-7 decreased significantly only in the TOC group (Fig. 1B).Conclusion:(1) The biologic DMARDs tested in this study did not significantly affect the serum levels of type I IFNs in this study.(2) The decrease in gp130 in the TOC group may imply that gp130 is induced by IL-6, although whether this level of decrease has physiological significance is open to question.(3) Serum IL-6 was significantly decreased in the TNFi group at 4 weeks but not 12 weeks. TNF has been reported to induce IL-6 (ref 2), but negative feedback loop(s) may be present. Such a feedback system might make the discontinuation of TNFi difficult, even if patients are in remission.(4) IL-7 may be a target of IL-6. A higher level of IL-7 has been reported to be present in the joints of RA patients compared with osteoarthrosis and it is a cytokine implicated in the differentiation of osteoclasts (ref 3). This may partly explain the effect of TOC on preventing bone erosion in RA.References:[1]Ann Rheum Dis. 2007; 66: 1008–14[2]Rheumatology 2007; 46: 920-6[3]Rheumatology 2008; 47: 753-9Acknowledgments:We thank all the members of the Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University. We are also grateful to the patients involved in this study.Disclosure of Interests:Kojiro Sato Grant/research support from: Abbie, Pfizer, Chugai, Astellas, Mitsubishi-Tanabe, Ono, Takeda, Sachiko Mamada: None declared, Chiyomi Hayashi: None declared, Takao Nagashima: None declared, Seiji Minota: None declared

Effect of Vitamin D Adjuvant and Allergen Specific Immunotherapy on Serum IL-10 and IL-17 Levels in Childhood Asthma: A Controlled Clinical Trial

2021 ◽  
Vol 30 (1) ◽  
pp. 175-181
Author(s):  
Lobna A. El-Korashi ◽  
Ola E. Nafea ◽  
Lamiaa G. Zake ◽  
Faika Arab ◽  
Reham H. Anis
Keyword(s):  
Childhood Asthma ◽  
Specific Immunotherapy ◽  
Pediatric Asthma ◽  
Serum Levels ◽  
Atopic Asthma ◽  
Subcutaneous Immunotherapy ◽  
Controlled Clinical Trial ◽  
Inhaled Corticosteroid ◽  
Allergen Specific Immunotherapy ◽  
Few Data

Background: 1, 25-dihydroxy vitamin D3 (VitD3) can improve the effect of allergenspecific immunotherapy (SIT). Few data is available about its role in childhood asthma. Objective: To assess the immunological and clinical efficacy of VitD3 as an adjuvant to allergen specific immunotherapy in pediatric asthma. Methodology: Sixty nine children with atopic asthma were divided into three groups: a group received subcutaneous immunotherapy (SCIT) in combination with VitD3 (n=23), another group received SCIT alone (n=23), and the last group VitD3 alone (n=23). All children were assessed at baseline, and six months for rate of inhaled corticosteroid (ICS) discontinuation, and serum levels of IL-10, and IL-17A. Results: In the SCIT + vitD3, ICS discontinuation rate was higher compared to VitD3 alone group and SCIT alone group at the end of 6th month (P=0.555 and 0.016 respectively). The combined SCIT+ VitD3 group showed significant increase of serum IL-10 level in comparison to SCIT alone group and VitD3 alone group (P=0.000) and significant decrease in serum IL-17A level compared to VitD3 alone group (P= 0.011) Conclusion: VitD3 enhance the clinical and immunological outcomes of SIT in pediatric asthma. Further investigation is needed to evaluate this effect in a larger scale to confirm its role as an adjunct to SIT.

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Long Term Effects ◽  
Allergen Specific Immunotherapy ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

High Frequency of RBC Transfusions in the STOP Study Was Associated with Reduction in Serum Biomarkers of Neurodegeneration, Vascular Remodeling and Inflammation

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 244-244 ◽  
Author(s):  
Hyacinth I Hyacinth ◽  
Beatrice E Gee ◽  
Jenifer H Voeks ◽  
Robert J. Adams ◽  
Jacqueline Hibbert
Keyword(s):  
Cerebral Ischemia ◽  
High Frequency ◽  
Low Frequency ◽  
Serum Levels ◽  
Arterial Remodeling ◽  
Serum Samples ◽  
Lower Serum ◽  
One Year ◽  
Loading Plot ◽  
Rbc Transfusion

Abstract Abstract 244 Stroke is a major cause of morbidity and mortality among children with sickle cell anemia (SCA). Children with SCA at risk for stroke can be identified by transcranial Doppler (TCD) ultrasound screening for abnormally high cerebral artery blood flow velocity and strokes can be prevented by chronic packed red blood cell (RBC) transfusion. However, the mechanisms that lead to cerebral vasculopathy and stroke in SCA and that explain the beneficial effects of chronic RBC transfusions in stroke prevention are poorly understood. We have previously shown that pre-treatment serum levels of brain derived neurotropic factor (BDNF) and platelet derived growth factor (PDGF) subtypes, biomarkers of cerebral ischemia and arterial remodeling, were associated with both high TCD velocity and development of stroke. We hypothesized that frequency of RBC transfusion would be associated with altered serum levels of neurodegenerative, inflammatory and angiogenic markers in SCA children with high TCD velocity and tested this hypothesis by assaying levels of these markers in post-STOP serum samples. Frozen serum samples drawn one year after subject's exit from the STOP clinical trial phase were utilized. Given the positive trial results, all but 9 subjects had been on chronic transfusion regimen for at least one year at the time of sample collection. Eighty samples were assayed using multiplex antibody immobilized beads (Millipore Corp, Billerica, MA). The mean fluorescent intensity was measured using the Milliplex xMAP system powered by Luminex (Bio-Rad, Hercules, CA). Ten biologically related neurodegenerative, inflammatory and angiogenic biomarkers were tested. The total number (frequency) of RBC transfusions recorded over the study period (4 years) for each participant was categorized into High (≥ 40), Moderate (20 – 39) or Low (< 20) frequency of transfusion. Median distribution with 10 – 90th percentile of the levels of biomarkers and TCD velocity were expressed using box-plots and the differences in median distribution between groups based on frequency of transfusion was estimated using Kruskal-Wallis test. A principal component analysis (PCA) loading plot was used to demonstrate the biological relationships between the biomarkers, taking into consideration linear correlations and spatial relationships between them. There were no significant differences in the hematological and anthropometric measures between groups. Overall, our result showed that low transfusion frequency was associated with high serum levels of biomarkers and vice versa, despite no significant difference in hemoglobin level between groups. The high frequency transfusion group had lower serum levels of BDNF (p = 0.02), sVCAM-1 (p < 0.001), PDGF-AA (p < 0.001), CCL5 (p < 0.01), tPAI-1 (p < 0.01) and NCAM (p < 0.01) levels compared with the low frequency transfusion group (figure 1 a – e). Although not shown in the figures, the same pattern was observed with TCD velocity which was lower (160, 115.7 – 204.9 cm/s) in the low compared with the high (195, 154 – 272 cm/s) frequency transfusion group. In addition, the medium frequency transfusion group had significantly lower serum sVCAM-1 (p < 0.01) compared with the low frequency transfusion group and higher PDGF-AA (p < 0.01) compared with the high frequency transfusion group. A PCA loading plot (figure 2) shows clustering of the biomarkers that are most closely biologically related, these are also the biomarkers that were significantly affected by the frequency of transfusion. Red blood cell transfusions in the STOP study were associated with reduced serum levels of biomarkers of angiogenesis (PDGF-AA and sVCAM-1), cerebral ischemia/neuronal survival adaptation (BDNF and NCAM) and inflammation (RANTES/CCL5), and this effect was most pronounced in the group with the highest frequency of transfusions (equivalent to most chronic transfusion regimen). This suggests that the protective effects of chronic RBC transfusions on stroke development in children with SCA may be attributable to improved cerebral perfusion, reduced inflammation and down-regulation of hypoxia-induced angiogenic responses that promote arterial remodeling. One or more in this group of biologically-related and relevant markers may be useful for monitoring children with SCA receiving stroke prevention therapies and for designing treatment targets. Disclosures: No relevant conflicts of interest to declare.

Serum levels and pharmacokinetic of rituximab in Bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial:

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7537-7537 ◽  
Author(s):  
M. Reiser ◽  
M. Wenger ◽  
C. Nickenig ◽  
N. Peter ◽  
B. Metzner ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Final Analysis ◽  
Serum Levels ◽  
Aggressive Lymphoma ◽  
Serum Samples ◽  
Elimination Phase ◽  
End Of Treatment ◽  
Pharmacokinetic Properties ◽  
Before And After ◽  
Dose Dense

7537 Background: The combination of Rituximab (R) and CHOP is considered the standard of treatment for DLBCL in elderly patients (pts) but there is hardly any data on the pharmacokinetic of Rituximab in aggressive lymphoma pts. The RICOVER-60 trial using Rituximab + bi-weekly CHOP-14 resulted in improved TTF in 828 elderly DLBCL pts (Blood 106:9a, 2005). Objective: To study serum levels and pharmacokinetic properties of Rituximab when combined with CHOP-14 in elderly DLBCL pts. Methods: Blood samples of 20 pts were taken before and after Rituximab infusion at each chemotherapy cycle. Additional samples were taken after the end of treatment and at the following time points: after 1 week, 1 month, 2 months, 3 months, 6 months and 9 months, respectively. Peak serum samples were taken within a maximum of 30 min, all samples were centrifuged at 1000 g for 10 min (room temperature) and stored at −20 degrees C. Batch samples were shipped to Xendo Laboratories, Groningen, The Netherlands, and analysed. Results: Samples from 20 pts were evaluable for this analysis with 16/20 pts having completed all 8 cycles of treatment, yet. The median (range) of serum Rituximab levels (μg/ml) before each cycle were: #1 0 (0–0); #2 39 (13–62); #3 74 (47–109); #4 95 (40–136); #5 111 (55–157); #6 114 (12–518); #7 125 (72–207);#8 116 (75–304). After therapy median (range) of serum Rituximab levels were: 163 (67–248) at 1 week; 101 (44–163) at 1 month; 55 (1–123) at 2 months; 34 (1–577) at 3 months; 5 (0–103) at 6 months; 1 (0–128) at 9 months. At 9 months samples from 7 pts were evaluable with detectable serum Rituximab levels in 4/7 pts. Conclusion: In the dose dense regimen R+CHOP-14 Rituximab levels increased after each subsequent cycle for the first 4 cycles. During cycle 5- 8 the serum Rituximab levels reached a plateau and decreased constantly after the end of treatment with detectable levels even after 9 months. Based on this data the German High Grade NHL Study Group (DSHNHL) further investigates a densification of Rituximab in the first cycles in order to improve treatment outcome. A final analysis of all 20 pts and a pharmacokinetic model of Rituximab distribution and elimination phase will be presented at the meeting. [Table: see text]

scholarly journals The investigation of allergic skin diseases susceptibility

2021 ◽  
Vol 2 (5) ◽  
Author(s):  
Prajwal Pandey ◽  
◽  
Wei Min Shi ◽  
Samir Shrestha ◽  
◽  
...  
Keyword(s):  
Skin Prick Test ◽  
Skin Diseases ◽  
Total Serum ◽  
Sample Population ◽  
Serum Ige ◽  
Prick Test ◽  
Clinical Allergy ◽  
Allergic Skin ◽  
One Year ◽  
Allergic Disorders

Background: Studies from around the world show that the prevalence and incidence of sensitization to allergens are higher in urban settings. Skin Prick Test (SPT) is being used more frequently now to investigate specific allergen sensitivity along with serum IgE level. Objective: The objective of our study was to evaluate the prevalence of sub-clinical allergy susceptibility and to see association with gender, season, age, urticaria, eczema, dermatitis and total serum IgE. Method and methodology: Eight hundred and ninety-two patients referred by dermatologist to rule out allergic sensitizations underwent SPT within one year. We calculated susceptible group and evaluated its ability to predict diseases like urticaria, eczema and non-specific dermatitis in general population. Result: The antigens that had the highest prevalence throughout the year were Mould II (32.38%) and Dermatophagoides farina (33.78%). The susceptibility to allergen was affected by season and age, however was not affected by gender. The predictability was highly statistically significant for Urticaria, Eczema and Non-specific Dermatitis. Conclusion: We conclude that the allergen susceptibility is high and is significantly correlated to the prevalence of allergic disorders in the sample population of a modern city like Shanghai. The susceptibility to allergen is affected by season and age. Keywords: skin prick test; total serum IgE; sub-clinical allergy susceptibility.

TARC and MDC Are the Only Chemokines with Highly Increased Levels in Serum of Hodgkin Lymphoma Patients.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2268-2268
Author(s):  
Marijke Niens ◽  
Lydia Visser ◽  
Ruth F. Jarrett ◽  
Gerard J. te Meerman ◽  
Sibrand Poppema ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Plasma Cells ◽  
Serum Levels ◽  
Control Group ◽  
P Value ◽  
Strongly Correlated ◽  
Serum Samples ◽  
Immunological Mechanisms ◽  
Before And After ◽  
Eosinophilic Granulocytes

Abstract Chemokines (cytokines with chemoattractant properties) can recruit different subsets of cells and therefore play an important role in the formation and maintenance of the non-neoplastic reactive infiltrate present in Hodgkin lymphoma (HL). The infiltrate consisting of lymphocytes, plasma cells, histiocytes and eosinophilic granulocytes is the most abundant part of the tumor mass in HL and surrounds the minority of neoplastic cells, the so-called Hodgkin-Reed Sternberg (HRS) cells. Several studies have shown that HRS cells and cells in the reactive infiltrate produce multiple chemokines. Especially TARC (CCL17) and MDC (CCL22) are highly produced by HRS cells. Altered serum chemokine levels might be related to HL prognosis or disease activity, since immunological mechanisms are crucial in HL pathogenesis. So far, only TARC and IL-8 levels have been studied in the serum of HL patients. In this study serum levels of nine chemokines including, Eotaxin, Fractalkine, IP10, MCP1, MDC, Mig, MIP1a, RANTES, and TARC were examined in serum of 163 untreated HL patients and 334 healthy controls using ELISA. In a subset of nine patients we also examined serum chemokine levels after treatment. Serum levels of TARC and MDC were significantly increased in 82% and 57% of the HL patient group compared to 12% and 5% in the control group, respectively. Serum Fractalkine and Mig levels did not show a difference between patients and controls, whereas serum levels of Eotaxin, IP10, MCP1, MIP1a, and RANTES were significantly decreased in HL patients. Analysis of the different subtypes revealed that the Nodular Sclerosis (NS) cases contained increased serum TARC and MDC levels compared to the Mixed Cellularity (MC) cases (p-value= 0,000). Serum TARC levels strongly correlated with serum MDC levels (r=0.82, p<0.01). Of the nine patients with serum samples before and after treatment, seven showed decreased serum TARC and MDC levels after treatment. One patient with increased levels before treatment did not show decrease in chemokine levels after treatment and died of disease. The last patient did not have increased chemokine levels before treatment and showed similar low levels in both serum samples. The other chemokines did not show a difference in serum levels in the before and after treatment samples. This is the first study testing a broad set of chemokines in serum of HL patients. Of all chemokines tested, TARC and MDC were the only chemokines with increased serum levels in the vast majority of HL patients and these can be used to monitor treatment efficiency.

scholarly journals Bone Demineralization in Postmenopausal Women: Role of Anamnestic Risk Factors

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Sandro La Vignera ◽  
Rosita A. Condorelli ◽  
Enzo Vicari ◽  
Chiara Nicoletti ◽  
Aldo E. Calogero
Keyword(s):  
Risk Factors ◽  
Postmenopausal Women ◽  
Nodular Goiter ◽  
Serum Levels ◽  
Fixed Dose ◽  
Mineral Density ◽  
Before And After ◽  
Group A ◽  
One Year ◽  
Group B

This study evaluated the effects of LT4 administration on the bone mineral density (BMD) in physiological postmenopausal women after two years of continuative treatment. 110 postmenopausal women with nodular goiter aged between 50 and 55 years were examined before and after 2 years of therapy with a fixed dose of LT4 (1.6 mcg/kg/die) for the treatment of nodular thyroid disease. The results showed that the patients on treatment with LT4 have a slight, but significant reduction of the BMD after 2 years of treatment, associated with increased serum levels of alkaline phosphatase and urinary excretion of hydroxyproline, confirming our data conducted on the same group after one year of therapy. Comparison between patients receiving LT4 (group A) or not (group B) showed that group A patients had significantly lower BMD. We demonstrated the statistically significant influence of the following risk factors on BMD: (1) body mass index<19 kg/m2; (2) the onset of menarche after the age of 15 years; (3) positive history for period of amenorrhoea; (4) nulliparity.

Sign in / Sign up

Export Citation Format

Share Document